265 related articles for article (PubMed ID: 22930710)
1. Small molecule allosteric modulation of the glucagon-like Peptide-1 receptor enhances the insulinotropic effect of oxyntomodulin.
Willard FS; Wootten D; Showalter AD; Savage EE; Ficorilli J; Farb TB; Bokvist K; Alsina-Fernandez J; Furness SG; Christopoulos A; Sexton PM; Sloop KW
Mol Pharmacol; 2012 Dec; 82(6):1066-73. PubMed ID: 22930710
[TBL] [Abstract][Full Text] [Related]
2. Differential impact of amino acid substitutions on critical residues of the human glucagon-like peptide-1 receptor involved in peptide activity and small-molecule allostery.
Koole C; Wootten D; Simms J; Miller LJ; Christopoulos A; Sexton PM
J Pharmacol Exp Ther; 2015 Apr; 353(1):52-63. PubMed ID: 25630467
[TBL] [Abstract][Full Text] [Related]
3. Positive Allosteric Modulation of the Glucagon-like Peptide-1 Receptor by Diverse Electrophiles.
Bueno AB; Showalter AD; Wainscott DB; Stutsman C; Marín A; Ficorilli J; Cabrera O; Willard FS; Sloop KW
J Biol Chem; 2016 May; 291(20):10700-15. PubMed ID: 26975372
[TBL] [Abstract][Full Text] [Related]
4. Modulation of the glucagon-like peptide-1 receptor signaling by naturally occurring and synthetic flavonoids.
Wootten D; Simms J; Koole C; Woodman OL; Summers RJ; Christopoulos A; Sexton PM
J Pharmacol Exp Ther; 2011 Feb; 336(2):540-50. PubMed ID: 21075839
[TBL] [Abstract][Full Text] [Related]
5. Two small molecule agonists of glucagon-like peptide-1 receptor modulate the receptor activation response differently.
Cheong YH; Kim MK; Son MH; Kaang BK
Biochem Biophys Res Commun; 2012 Jan; 417(1):558-63. PubMed ID: 22177947
[TBL] [Abstract][Full Text] [Related]
6. Demonstration of the innate electrophilicity of 4-(3-(benzyloxy)phenyl)-2-(ethylsulfinyl)-6-(trifluoromethyl)pyrimidine (BETP), a small-molecule positive allosteric modulator of the glucagon-like peptide-1 receptor.
Eng H; Sharma R; McDonald TS; Edmonds DJ; Fortin JP; Li X; Stevens BD; Griffith DA; Limberakis C; Nolte WM; Price DA; Jackson M; Kalgutkar AS
Drug Metab Dispos; 2013 Aug; 41(8):1470-9. PubMed ID: 23653442
[TBL] [Abstract][Full Text] [Related]
7. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
8. Comparison of stability, cellular, glucose-lowering and appetite supressing effects of oxyntomodulin analogues modified at the N-terminus.
Lynch AM; Pathak N; Flatt YE; Gault VA; O'Harte FP; Irwin N; Flatt PR
Eur J Pharmacol; 2014 Nov; 743():69-78. PubMed ID: 25246014
[TBL] [Abstract][Full Text] [Related]
9. New screening strategy and analysis for identification of allosteric modulators for glucagon-like peptide-1 receptor using GLP-1 (9-36) amide.
Nakane A; Gotoh Y; Ichihara J; Nagata H
Anal Biochem; 2015 Dec; 491():23-30. PubMed ID: 26341912
[TBL] [Abstract][Full Text] [Related]
10. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
Ligumsky H; Wolf I; Israeli S; Haimsohn M; Ferber S; Karasik A; Kaufman B; Rubinek T
Breast Cancer Res Treat; 2012 Apr; 132(2):449-61. PubMed ID: 21638053
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of oxyntomodulin and GLP-1 on glucose metabolism.
Du X; Kosinski JR; Lao J; Shen X; Petrov A; Chicchi GG; Eiermann GJ; Pocai A
Am J Physiol Endocrinol Metab; 2012 Jul; 303(2):E265-71. PubMed ID: 22621866
[TBL] [Abstract][Full Text] [Related]
12. The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.
Moon HS; Kim MK; Son MH
Arch Pharm Res; 2011 Jul; 34(7):1041-3. PubMed ID: 21811909
[TBL] [Abstract][Full Text] [Related]
13. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties.
Bhat VK; Kerr BD; Flatt PR; Gault VA
Biochem Pharmacol; 2013 Jun; 85(11):1655-62. PubMed ID: 23518155
[TBL] [Abstract][Full Text] [Related]
14. Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets.
Sloop KW; Willard FS; Brenner MB; Ficorilli J; Valasek K; Showalter AD; Farb TB; Cao JX; Cox AL; Michael MD; Gutierrez Sanfeliciano SM; Tebbe MJ; Coghlan MJ
Diabetes; 2010 Dec; 59(12):3099-107. PubMed ID: 20823098
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide-1 inhibits insulinotropic effects of oxyntomodulin and glucagon in cattle.
ThanThan S; Saito T; Yannaing S; Zhao H; Nakashima K; Kuwayama H
Domest Anim Endocrinol; 2012 Apr; 42(3):155-64. PubMed ID: 22154917
[TBL] [Abstract][Full Text] [Related]
16. Differential activation and modulation of the glucagon-like peptide-1 receptor by small molecule ligands.
Wootten D; Savage EE; Willard FS; Bueno AB; Sloop KW; Christopoulos A; Sexton PM
Mol Pharmacol; 2013 Apr; 83(4):822-34. PubMed ID: 23348499
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors.
Darbalaei S; Yuliantie E; Dai A; Chang R; Zhao P; Yang D; Wang MW; Sexton PM; Wootten D
Biochem Pharmacol; 2020 Oct; 180():114150. PubMed ID: 32682761
[TBL] [Abstract][Full Text] [Related]
18. Ligand-specificity of the rat GLP-I receptor recombinantly expressed in Chinese hamster ovary (CHO-) cells.
Fehmann HC; Jiang J; Schweinfurth J; Dörsch K; Wheeler MB; Boyd AE; Göke B
Z Gastroenterol; 1994 Apr; 32(4):203-7. PubMed ID: 8017094
[TBL] [Abstract][Full Text] [Related]
19. Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening.
Koole C; Wootten D; Simms J; Valant C; Sridhar R; Woodman OL; Miller LJ; Summers RJ; Christopoulos A; Sexton PM
Mol Pharmacol; 2010 Sep; 78(3):456-65. PubMed ID: 20547734
[TBL] [Abstract][Full Text] [Related]
20. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice.
Maida A; Lovshin JA; Baggio LL; Drucker DJ
Endocrinology; 2008 Nov; 149(11):5670-8. PubMed ID: 18669601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
